Research in Allergic Rhinitis
Omalizumab reduces the risk of anaphylaxis in patients who are receiving immunotherapy. SLIT has been suggested to bring about a significant reduction in symptoms.
New and better new immune-based therapies are being searched for. Drugs called Anti–immunoglobulin E Antibodies (Omalizumab) have been evaluated in the treatment of Seasonal Allergic Rhinitis (SAR). Omalizumab reduces the risk of anaphylaxis in patients who are receiving immunotherapy. It is however expensive. Novel Forms of Immunotherapy that are associated with lower risk for fatal body reactions (anaphylaxis) are also being developed. Sublingually administered allergen immunotherapy (SLIT) has been suggested to bring about a significant reduction in symptom and medication scores in patients with
